Thoratec Corporation (NASDAQ:THOR): Thoratec trades down after UBS cut the shares to Neutral from Buy on valuation. The firm says the stock may be played out over the near term, as peer competitor Heartware’s (NASDAQ:HTWR) pending launch of HVAD is expected to cut into its heart therapy market share. The shares closed at $30.40, down $1.22, or 3.86%, on the day. Its market capitalization is $1.82 billion.
This is all good for HIN. Just wish the FDA would get on with it!!
HIN Price at posting:
$1.89 Sentiment: Buy Disclosure: Held
